Pimecrolimus


Concise Prescribing Info
Indications/Uses
Mild to moderate atopic dermatitis.
Dosage/Direction for Use
Adult : Topical/Cutaneous As 1% cream: Apply thinly onto affected area bid until signs and symptoms resolve. Discontinue treatment if no improvement after 6 wk.
Dosage Details
Topical/Cutaneous
Atopic dermatitis
Adult: Mild to moderate: As 1% cream: Apply thinly onto affected area bid until signs and symptoms resolve. Discontinue treatment if no improvement after 6 wk.
Child: ≥2 yr: Same as adult dose.
Contraindications
Immunocompromised patients.
Special Precautions
Patient w/ malignant or pre-malignant skin conditions (e.g. cutaneous T-cell lymphoma), severe atopic dermatitis, generalised erythroderma, skin disease which may increase systemic absorption (e.g. Netherton’s Syndrome). Pregnancy and lactation.
Adverse Reactions
Significant: Application site reactions (e.g. burning, stinging, soreness, pruritus, erythema, folliculitis), viral and bacterial skin infections (e.g. varicella zoster virus infection, herpes simplex virus infection), lymphadenopathy, skin papilloma. Rarely, malignancy (e.g. skin cancer and lymphoma).
Nervous: Headache.
Resp: Nasopharyngitis, upper resp tract infection, cough, bronchitis, rhinitis.
Dermatologic: Impetigo, urticaria.
Immunologic: Influenza.
Others: Fever.
Patient Counseling Information
Avoid unnecessary exposure to sun and UV light during treatment. Avoid use of occlusive dressing or wrappings.
Action
Description: Pimecrolimus, a macrolactam derivative of ascomycin, is an immunosuppressant. It inhibits calcineurin thereby blocking the activation and proliferation of T-cells and prevents the release of inflammatory cytokines and mediators from mast cells.
Pharmacokinetics:
Absorption: Time to peak plasma concentration: 2-6 hr.
Distribution: Plasma protein binding: 99.5%, mainly to lipoproteins.
Metabolism: Metabolised in the liver by CYP 3A4 enzyme.
Excretion: Via faeces (78.4%, as metabolites; <1%, as unchanged drug); urine (2.5%, as metabolites).
Chemical Structure

Click on icon to see table/diagram/image
Storage
Store at 25°C. Avoid contact w/ skin or mucous membranes by wearing gloves and protective equipment. Wash hands before and after handling.
ATC Classification
D11AH02 - pimecrolimus ; Belongs to the class of agents for atopic dermatitis, excluding corticosteroids. Used in the treatment of atopic dermatitis.
Disclaimer: This information is independently developed by MIMS based on Pimecrolimus from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in